CMS Administrator Mehmet Oz clarified that a deal has not yet been sealed with the manufacturer of semaglutide, Novo Nordisk, ...

Under the terms of the deal, Gilead will put down $120 million in an upfront payment and will promise up to $1.52 billion in ...

The Commissioner’s National Priority Voucher awards companies that align with specific national priorities—such as boosting ...

EMD Serono will offer its fertility treatments on TrumpRx at a steep discount, and Roche’s direct-to-consumer offering will ...

Veradermics is the second hair regrowth specialist to fundraise this week, after Pelage Pharmaceuticals announced Wednesday ...

The company is pursuing a Phase III trial for its topical stem cell-rejuvenating molecule that aims to reactivate hair growth ...

Johnson & Johnson has yet to make a drug pricing deal with Trump; Novo makes more moves under new CEO; more than 1,000 laid ...

Kailera’s lead asset, KAI-9531, elicited an average weight loss of more than 17% in a Phase III study in China. The biotech ...

Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene ...

Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...

During this webinar BioSpace sits down with former FDA Chief Information Officer Vid Desai to discuss the potential ...

Novo had around 250 employees working on cell therapies, all of whom will be laid off, though a spokesperson declined to ...